131 related articles for article (PubMed ID: 37482138)
41. Expression of a restrictive receptor for interleukin 13 is associated with glial transformation.
Debinski W; Slagle B; Gibo DM; Powers SK; Gillespie GY
J Neurooncol; 2000 Jun; 48(2):103-11. PubMed ID: 11083073
[TBL] [Abstract][Full Text] [Related]
42. Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
Stastny MJ; Brown CE; Ruel C; Jensen MC
J Pediatr Hematol Oncol; 2007 Oct; 29(10):669-77. PubMed ID: 17921847
[TBL] [Abstract][Full Text] [Related]
43. TGFαL3-SEB fusion protein as an anticancer against ovarian cancer.
Maleki F; Sadeghifard N; Sedighian H; Bakhtiyari S; Hosseini HM; Fooladi AAI
Eur J Pharmacol; 2020 Mar; 870():172919. PubMed ID: 31935394
[TBL] [Abstract][Full Text] [Related]
44. Development of antibodies against recombinant staphylococcal enterotoxin B from food poisoning cases.
Purwanasari HN; Salasia SIO; Aziz F; Wasissa M; Lestari FB; Santosa CM
Vet World; 2024 Jan; 17(1):131-135. PubMed ID: 38406354
[TBL] [Abstract][Full Text] [Related]
45. Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.
Shimamura T; Fujisawa T; Husain SR; Joshi B; Puri RK
Clin Cancer Res; 2010 Jan; 16(2):577-86. PubMed ID: 20068108
[TBL] [Abstract][Full Text] [Related]
46. Receptor for interleukin 13 is abundantly and specifically over-expressed in patients with glioblastoma multiforme.
Debinski W; Gibo DM; Slagle B; Powers SK; Gillespie GY
Int J Oncol; 1999 Sep; 15(3):481-6. PubMed ID: 10427128
[TBL] [Abstract][Full Text] [Related]
47. Tumor targeted delivery of doxorubicin in malignant peripheral nerve sheath tumors.
Madhankumar AB; Mrowczynski OD; Slagle-Webb B; Ravi V; Bourcier AJ; Payne R; Harbaugh KS; Rizk E; Connor JR
PLoS One; 2018; 13(1):e0181529. PubMed ID: 29304038
[TBL] [Abstract][Full Text] [Related]
48. Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.
Sengupta S; Thaci B; Crawford AC; Sampath P
Biomed Res Int; 2014; 2014():952128. PubMed ID: 25247196
[TBL] [Abstract][Full Text] [Related]
49. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
Han J; Yang L; Puri RK
J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
[TBL] [Abstract][Full Text] [Related]
50. Novel way to increase targeting specificity to a human glioblastoma-associated receptor for interleukin 13.
Debinski W; Gibo DM; Puri RK
Int J Cancer; 1998 May; 76(4):547-51. PubMed ID: 9590132
[TBL] [Abstract][Full Text] [Related]
51. Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas.
Pawlowski KD; Duffy JT; Tiwari A; Zannikou M; Balyasnikova IV
Cells; 2023 Jun; 12(13):. PubMed ID: 37443750
[TBL] [Abstract][Full Text] [Related]
52. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T; Husain SR; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
[TBL] [Abstract][Full Text] [Related]
53. Oral administration of recombinant Bacillus subtilis spores expressing mutant staphylococcal enterotoxin B provides potent protection against lethal enterotoxin challenge.
Xiong Z; Mai J; Li F; Liang B; Yao S; Liang Z; Zhang C; Gao F; Ai X; Wang J; Long Y; Yang M; Gong S; Zhou Z
AMB Express; 2020 Dec; 10(1):215. PubMed ID: 33315153
[TBL] [Abstract][Full Text] [Related]
54. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
55. Targeting IL-13Ralpha2-positive cancer with a novel recombinant immunotoxin composed of a single-chain antibody and mutated Pseudomonas exotoxin.
Kioi M; Seetharam S; Puri RK
Mol Cancer Ther; 2008 Jun; 7(6):1579-87. PubMed ID: 18566228
[TBL] [Abstract][Full Text] [Related]
56. Preparation and In Vitro Evaluation of Antitumor Activity of TGFαL3-SEB as a Ligand-Targeted Superantigen.
Yousefi F; Mousavi SF; Siadat SD; Aslani MM; Amani J; Rad HS; Fooladi AA
Technol Cancer Res Treat; 2016 Apr; 15(2):215-26. PubMed ID: 25759426
[TBL] [Abstract][Full Text] [Related]
57. Construction of IL-13 Receptor α2-Targeting Resveratrol Nanoparticles against Glioblastoma Cells: Therapeutic Efficacy and Molecular Effects.
Lin XM; Shi XX; Xiong L; Nie JH; Ye HS; Du JZ; Liu J
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638961
[TBL] [Abstract][Full Text] [Related]
58. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.
Brown CE; Aguilar B; Starr R; Yang X; Chang WC; Weng L; Chang B; Sarkissian A; Brito A; Sanchez JF; Ostberg JR; D'Apuzzo M; Badie B; Barish ME; Forman SJ
Mol Ther; 2018 Jan; 26(1):31-44. PubMed ID: 29103912
[TBL] [Abstract][Full Text] [Related]
59. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.
Husain SR; Joshi BH; Puri RK
Int J Cancer; 2001 Apr; 92(2):168-75. PubMed ID: 11291041
[TBL] [Abstract][Full Text] [Related]
60. Development of sandwich chemiluminescent immunoassay based on an anti-staphylococcal enterotoxin B Nanobody-Alkaline phosphatase fusion protein for detection of staphylococcal enterotoxin B.
Sun T; Zhao Z; Liu W; Xu Z; He H; Ning B; Jiang Y; Gao Z
Anal Chim Acta; 2020 Apr; 1108():28-36. PubMed ID: 32222241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]